Bleeding complications with glycoprotein IIb/IIIa inhibitors

Drugs of Today

Volumn 36, Issue 8, 2000, Pages 503-514

  Iqbal, O ^a   Walenga, J M ^a   Lewis, B E ^a   Bakhos, M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; ROXIFIBAN; SIBRAFIBAN; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; XEMILOFIBAN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

EID: 0033776378     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.8.591832     Document Type: Review

References (57)

1. The platelet membrane GPIIb/IIIa complex
2. Antiplatelet therapy and the prevention of thrombosis
3. Thrombolysis in Myocardial Infarction (TIMI) trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
4. International randomized trial comparing four thrombolytic strategies for acute myocardial infarction
5. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
6. Practice strategies for elective red cell transfusion
7. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention: The EPIC investigators
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
9. Standard versus low dose weight adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
10. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
11. An overview of platelet GPIIb/IIIa receptor antagonists trials
12. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
13. Accelerated-dose eptifibatide (Integrilin) in elective coronary stenting: Preliminary results of the ESPRIT trial
14. Multicenter, randomized, double-blind placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, Integrilin, in elective coronary intervention
15. Immediate and reversible platelet-inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
16. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention
17. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: NICE guys finish first
18. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
19. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective
20. Tirofiban
21. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
22. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
23. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
24. Optimal dosing of a platelet glycoprotein IIb-IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes: Results from the PARAGON B study
25. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
26. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
27. Tirofiban - An overview of the phase III trials
28. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
29. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the TAMI 8 pilot study
30. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow patency outcome in the thrombolysis and angioplasty in myocardial infarction trials
31. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early complete infarct artery reperfusion
32. INTRO-AMI: Marked enhancement of arterial patency with eptifibatide and low-dose alteplase in acute myocardial infarction
33. Combined therapy with streptokinase and integrilin
34. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation reperfusion gain in myocardial infarction trial
35. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators
36. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions
37. Sustained glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
38. Pharmacodynamic efficacy, clinical safety outcomes following prolonged platelet glycoprotein IIb/IIIa blockade with oral xemilofiban: Results of a multi-center placebo-controlled randomized trial
39. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients with acute coronary syndrome: Results of the TIMI-12 trial
40. A randomized comparison of sibrafiban, an oral glycoprotein IIb/IIIa receptor antagonist, with and without aspirin versus aspirin after acute coronary syndromes: Results of the 2nd SYMPHONY trial
41. Platelet glycoprotein IIb/IIIa receptor blockade and low-molecular-weight heparins in interventional practice: A new standard?
42. Monitoring platelet GPIIb/IIIa antagonist therapy
43. Rapid and simple platelet function assay to assess glycoprotein IIb/IlIa receptor blockade
44. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy
45. Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: Are we missing something?
46. Overview of glycoprotein IIb/IIIa clinical trials with abciximab and eptifibatide in acute coronary syndromes and percutaneous coronary intervention
47. Effect of calcium on GPIIb/IIIa interactions with integrilin-enhanced GPIIb/IIIa binding and inhibition of platelet aggregation by reduction in the concentration of ionized calcium in plasma anticoagulated with citrate
48. Effect of anticoagulation and platelet agonist concentration on the inhibitory activities of glycoprotein IIb/IIIa antagonists
49. Safety issues surrounding use of platelet GPIIb/IIIa antagonists: Reversibility readministration
50. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
51. Ticlopidine potentiates abciximab's ability to inhibit ADP-induced platelet aggregation in vitro
52. Safe use of platelet GPIIb/IIIa inhibitors
53. Abciximab readministration for coronary interventions: Is it safe?
54. Bleeding risk of combined oral anticoagulant and antiplatelet therapy in cardiovascular disease
55. Inhibition of platelet aggregation with a GPIIb/IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction
56. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis
57. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents